Naturally Immune For Life

For many years, scientists believed that human milk oligosaccharides (HMOs) primarily served as food for beneficial bacteria in the infant gut. While this important function remains true, recent research has revealed that HMOs do much more than nourish the microbiome. They can also interact directly with immune cells and help shape the developing immune system.

Numerous studies have shown that breastfeeding is associated with a reduced risk of infectious diseases, inflammatory disorders, asthma, allergies, and certain autoimmune conditions. Among the many bioactive compounds found in breast milk, human milk oligosaccharides (HMOs) are believed to be major contributors to these protective effects. HMOs are a highly diverse group of complex carbohydrates, with more than 1,000 distinct structures identified to date. These oligosaccharides consist of both short-chain and long-chain molecules, typically present in an approximate ratio of 9:1, creating a unique biological system that supports both microbial and immune development during early life.

Dendritic Cells: The Immune System’s Programmers

Dendritic cells act as sentinels throughout the body. They constantly sample their environment, detecting microbes, food proteins, and other substances. Once they encounter something new, they present that information to T cells, helping determine whether the immune system should launch an attack or develop tolerance. This process is especially important during infancy. Newborns are suddenly exposed to countless bacteria, viruses, and environmental antigens after birth. Their immune systems must learn to distinguish between harmful threats and harmless substances without triggering excessive inflammation. One special type of dendritic cell, known as a tolerogenic dendritic cell, promotes immune balance. These cells help generate regulatory T cells (Tregs), which act as the immune system’s brakes, preventing unnecessary immune reactions and excessive inflammation.

HMOs Promote Immune Tolerance

Researchers isolated a natural mixture of HMOs from human milk and exposed human dendritic cells to these compounds in the laboratory. They discovered that HMOs encouraged dendritic cells to adopt a semi-mature, regulatory state rather than a fully inflammatory one. The HMO-treated cells produced increased amounts of important anti-inflammatory signaling molecules, including interleukin-10 (IL-10) and interleukin-27 (IL-27). Both cytokines are known to support immune tolerance and help control inflammation. At the same time, HMOs did not significantly increase production of inflammatory cytokines such as interleukin-12 (IL-12) and tumor necrosis factor-alpha (TNF-α), which are commonly associated with aggressive immune responses. This combination of increased regulatory signals and limited inflammatory activity suggests that HMOs help educate the immune system to remain balanced during early life.

Protecting Against Excessive Inflammation

The researchers also investigated what happens when immune cells encounter inflammatory stimuli. They exposed dendritic cells to lipopolysaccharide (LPS), a bacterial component that normally triggers strong inflammatory responses. As expected, LPS caused dendritic cells to become highly activated and release inflammatory cytokines. However, when HMOs were added alongside LPS, the inflammatory response was significantly reduced. HMOs suppressed the production of IL-12, IL-6, and TNF-α while maintaining elevated levels of regulatory cytokines such as IL-10. In other words, HMOs did not shut down immunity entirely; instead, they helped prevent excessive inflammation while preserving immune balance.

HMOs Increase Regulatory T Cells

Perhaps the most important finding was the effect of HMOs on T-cell development. Dendritic cells treated with HMOs were significantly more likely to induce regulatory T cells from naïve T cells. Naïve T cells are immature immune cells that have not yet encountered a specific antigen and are awaiting activation to develop into specialized T-cell populations. Regulatory T cells are critical for preventing autoimmune reactions and maintaining tolerance to beneficial microbes, foods, and environmental substances. The study found that these Tregs were not only increased in number but were also functionally active, capable of suppressing excessive immune responses. This finding provides a potential explanation for why breastfeeding has been linked to lower risks of asthma, allergies, inflammatory bowel disease, and autoimmune conditions.

A Direct Link Between Breast Milk and Immune Development

The study also identified two receptors, DC-SIGN and TLR4, that appear to help dendritic cells recognize HMOs. Through these interactions, HMOs can directly influence immune cell behavior independently of their effects on the microbiome. These discoveries highlight the remarkable complexity of human milk. HMOs are not simply nutrients or prebiotics; they are bioactive molecules that actively participate in immune education. By promoting regulatory dendritic cells, increasing IL-10 production, expanding regulatory T cells, and reducing excessive inflammation, HMOs help establish immune tolerance during one of the most critical periods of human development.

HMOs can begin influencing gut bacteria and immune cells within days, measurable microbiome changes often occur within 1–4 weeks, and broader immune adaptations likely develop over several months of continued exposure. In breastfed infants, this process begins immediately after birth and contributes to immune programming throughout early life.

As researchers continue to uncover the many functions of HMOs, it is becoming increasingly clear that these unique components of breast milk play a fundamental role in building a resilient and balanced immune system that can benefit health throughout life.

*Evidence based timeline from the article reference for HMO’s establishing tolerance can be purchased below (Common Supplements, Fermented Foods, and Digestive Support).